Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2016-02-01 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company to the SEC staff regarding comments on a Draft Registration Statement on Form S-1. It discusses revisions and clarifications to the registration statement, including risk factors, use of proceeds, capitalization, and other disclosures related to an initial public offering (IPO). The presence of detailed responses to SEC comments on a registration statement indicates this is part of the registration process for securities offering, specifically related to Form S-1 filings. This is not a financial report, earnings release, or other types of filings but a regulatory correspondence related to a capital raising process. Therefore, the document is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2016-02-01 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, use of proceeds, management discussion and analysis, and other disclosures typical of an IPO prospectus. This type of filing is related to capital raising and financing activities rather than a financial report, management change, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Confidence is high due to the clear identification of the form and content.
2016-02-01 English
Regulatory Filings 2016
Regulatory Filings
2016-01-04 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Moleculin Biotech, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes details about the offering, underwriting, risk factors, and company overview, typical of a prospectus related to a capital raising event. This is not an annual report, earnings release, or management discussion, but a capital/financing update related to the company's IPO process. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2015-12-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.